Year-to-date sales at Roche rise 5%, with 10% growth in the USA

19 October 2017

Swiss pharma giant Roche (ROG: SIX) says its third-quarter 2017 sales were 13.1 billion Swiss francs ($13.37 billion), compared to the 13.04 billion francs average estimate by analysts in a Reuters poll, boosted by better-than-expected revenue from its new multiple sclerosis medicine Ocrevus (ocrelizumab).

Sales of Ocrevus in the third quarter were 308 million francs, beating the poll average of 228 million and growing from192 million francs in the second quarter.

Sales figures for the first nine months of 2017 showed that overall revenues rose 5% to 39.4 billion francs. Roche does not disclose earnings figures at the quarterly stage.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK